Products
Spartalizumab Biosimilar Monoclonal Antibody (PD-1) for Research
Pre-Made Spartalizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Spartalizumab (INN; development code PDR001) is a monoclonal antibody that is being investigated for melanoma.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-531-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Spartalizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
| INN Name | Spartalizumab |
| Target | PDCD1/PD-1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer |
| Conditions Discontinued | Neuroendocrine tumours |
| Development Tech | na |
About target - PDCD1
1. Protein Programmed cell death 1 ligand 1
2. Gene CD274
3. Organism Homo sapiens (Human)
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
